Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET
Company Participants
Justine Koenigsberg - VP, IR
Nello Mainolfi - Founder, President and CEO
Jared Gollob - CMO
Bruce Jacobs - CFO
Conference Call Participants
Brad Canino - Stifel
Gospel M. Enyindah-Asonye - Morgan Stanley
Marc Frahm - TD Cowen
Eric Joseph - JPMorgan
Srikripa Devarakonda - Truist Securities
Derek Archila - Wells Fargo
Chris Shibutani - Goldman Sachs
Kalpit Patel - B. Riley Securities
Operator
Good day, and welcome to the Kymera Therapeutics Third Quarter 2023 Results Call. [Operator Instructions]. Please note that this event is being recorded.
I'd like to turn the conference over to Ms. Justine Koenigsberg, Vice President of Investor Relations. Please go ahead.
Justine Koenigsberg
Good morning, and welcome to Kymera's Quarterly Update. Joining me on this morning's call are Nello Mainolfi, Founder, President, and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, Chief Financial Officer. Following our remarks and presentation, we will open the call to questions. During the Q&A portion of the call, please limit your question to one and a related follow-up so that we will have enough time to address everyone's questions.
Please note that we will be referencing slides in our corporate presentation during Jared's remarks. The slides can be accessed in the Investors section of our website, under Events and Presentations, and will be shown during the call for those on the webcast. Before we begin, today's discussion will include forward-looking statements about our future expectations, plans, and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call.
With that, I would now like to turn the call over to Nello.
Nello Mainolfi
Thank you, Justine, and thanks, everybody, for joining us today. We're excited to review our recent progress and several critical milestones that the company has achieved. As we are near the end of 2023, I'm extremely proud of the strong execution by our team that has led to continued progress in our clinical studies across multiple programs along with innovative pipeline advancements to support our future growth.
Before we detail that progress, I want to share a few thoughts on where Kymera is in our mission to building a best-in-class, fully integrated, global degrader medicine company. In doing so, I hope to provide you with an important lens through which you can view our achievements and our strategic decisions regarding the portfolio.